Cancer Drug Price Caps in India: How the New 30% Trade Margin Rule Works

Current development: On 8 October 2026, the Department of Pharmaceuticals announced that the Union government had approved a proposal to restrict trade margins on non-scheduled anti-cancer medicines to 30% of their Maximum Retail Price (MRP).

Media reports, citing government officials, indicate that the measure is expected to cover approximately 110 medicines, including around 35 patented medicines.

The intervention is intended to cover branded, generic, domestically manufactured and imported versions of the selected medicines.

Government's objective: The main aim is to reduce excessive price increases between the initial sale of a medicine to the distribution chain and its final sale to patients.

The government estimates that the measure could reduce MRPs by up to 70% in certain cases and generate approximately ₹2,500 crore in annual patient savings.

These are projected benefits, not reductions already achieved across the market.

Reason for intervention: Medicines used in cancer treatment can be extremely expensive, particularly newer targeted therapies and immunotherapies.

Patients often require treatment over several months or years, increasing the financial burden on households.

Current implementation status: The government's approval does not mean that the final list of 110 medicines has already been notified.

An expert committee under the Directorate General of Health Services (DGHS) is responsible for finalising the medicines to be covered. The National Pharmaceutical Pricing Authority (NPPA) must then take the necessary decision and issue the regulatory notification.

As a result, the scope and enforceability of the new cap must be distinguished from the policy announcement itself.

UPSC significance: The decision illustrates the government's role in regulating markets when essential goods become unaffordable, particularly where serious illness limits consumers' ability to postpone treatment or choose alternatives.

Complex treatment: Cancer is not a single disease. It refers to a group of diseases characterised by the uncontrolled growth and spread of abnormal cells.

Different cancers require different combinations of surgery, radiation, medicines and supportive care.

Advanced medicines: Some newer cancer treatments are developed for specific molecular features of tumours or for modifying the immune system's response to cancer.

These therapies may involve substantial research, clinical testing and specialised manufacturing.

Research and development: Pharmaceutical companies invest in laboratory research, clinical trials, safety evaluation, regulatory approval and the development of manufacturing systems.

Companies often cite these investments when explaining the prices of innovative treatments.

Patent protection: Patents may provide temporary exclusive rights over qualifying pharmaceutical inventions.

During the period of patent protection, competing manufacturers may be unable to produce the patented medicine without authorisation or another lawful basis.

This can limit price competition.

Trade margins: Prices may rise as medicines move through distributors, stockists, retailers and hospital pharmacies.

High trade margins can make medicines more expensive even when their initial selling price is substantially lower than the MRP.

Limited patient choice: Cancer patients may require a particular treatment based on medical evidence, tumour characteristics and their health condition.

They cannot always switch to a cheaper medicine without affecting treatment.

Market characteristics: The market for many specialised cancer medicines has limited competition, high information asymmetry and urgent consumer demand.

Information asymmetry means that one party, such as a manufacturer or medical professional, has substantially more technical information than the consumer.

These conditions can reduce the effectiveness of ordinary market competition in controlling prices.

Meaning: Trade Margin Rationalisation (TMR) is a regulatory approach that limits the difference between the price at which a medicine enters the distribution chain and its final retail price.

It seeks to prevent excessive mark-ups without necessarily fixing the basic price at which manufacturers sell the product.

Price to Stockist (PTS): This is the price at which a manufacturer sells a medicine to a stockist or first distributor.

Maximum Retail Price (MRP): This is the maximum price printed on a product that can be charged to the consumer, inclusive of applicable taxes.

Trade margin: For the proposed arrangement, the relevant margin is calculated with reference to the MRP:

Trade Margin (%) = (MRP-PTS) / (MRP) × 100

Illustration: Suppose a medicine is supplied to a stockist for ₹700.

Under a 30% trade-margin cap calculated on MRP, its maximum permitted retail price would be ₹1,000 in this simplified example.

The illustration excludes tax complications and other adjustments that may arise under the applicable notification.

Important mathematical distinction: A 30% margin calculated on MRP is not the same as adding 30% to the price to stockist.

A margin of ₹300 on an MRP of ₹1,000 represents 30% of MRP but approximately 42.86% of the ₹700 stockist price.

Effect of the cap: If the existing MRP of a medicine contains a much larger trade margin, manufacturers would need to revise its MRP downward to comply with the notified limit.

Regulatory limitation: TMR controls the distribution margin, not necessarily the manufacturer's initial selling price or manufacturing cost.

This distinction is central to understanding both the benefits and limitations of the new proposal.

India's pharmaceutical regulatory framework uses different methods for controlling medicine prices.

Conventional ceiling-price regulation: Under this mechanism, NPPA fixes the maximum permissible price for a specified drug formulation covered by the relevant provisions.

Manufacturers cannot sell the regulated formulation above the applicable ceiling, with permitted taxes added as prescribed.

Trade-margin regulation: Under TMR, the regulator restricts the permissible margin between the first sale to the distribution chain and the final MRP.

The initial stockist price may remain commercially determined unless separately regulated.

Formulation: A formulation is the final medicinal product in a particular pharmaceutical form and strength, such as a 100 mg tablet or an injectable solution.

Why TMR is being used: A cancer medicine may be sold under several brands, strengths and packaging arrangements.

Applying a common trade-margin rule can offer a practical mechanism for regulating high mark-ups across multiple products.

Non-scheduled formulations remain subject to relevant provisions of the Drugs (Prices Control) Order, including restrictions on annual MRP increases.

Scheduled medicines: These are formulations included in Schedule I of the Drugs (Prices Control) Order, 2013.

The Schedule is linked to the National List of Essential Medicines (NLEM) published by the Ministry of Health and Family Welfare.

NPPA fixes ceiling prices for scheduled formulations under the applicable regulatory framework.

Non-scheduled medicines: These are formulations not covered by Schedule I.

Their manufacturers generally have greater flexibility in initially determining MRPs, subject to applicable law.

Annual price-increase restriction: Under Paragraph 20 of DPCO, 2013, manufacturers of non-scheduled formulations cannot increase their MRP by more than 10% during the preceding 12-month period.

This provision restricts the rate of price increases. It does not necessarily ensure that the original MRP is affordable.

Difference in price regulation: Scheduled medicines are subject to government-determined price ceilings.

Non-scheduled medicines are generally monitored for excessive annual MRP increases and can become subject to additional public-interest interventions.

Why cancer medicines are important: Several essential cancer treatments already have notified ceiling prices, while many newer or specialised medicines remain outside ordinary scheduled-price controls.

Relevance of the new decision: The proposed TMR expansion is directed at this second category.

It seeks to restrict excessive distribution margins on expensive non-scheduled cancer medicines.

Meaning: The National List of Essential Medicines (NLEM) identifies medicines considered important for meeting the priority healthcare needs of the population.

The list is prepared by the Ministry of Health and Family Welfare.

Purpose: NLEM supports rational medicine selection, public procurement, drug-price regulation, medical education and healthcare planning.

Selection principles: Medicines are considered using factors such as public-health relevance, efficacy, safety, comparative therapeutic value and cost-effectiveness.

Cost-effectiveness: Cost-effectiveness compares the health benefit delivered by a treatment with the resources required to provide it.

It does not simply mean selecting the cheapest available medicine.

Current reference list: NLEM 2022 is the relevant national list incorporated into the current scheduled-price framework.

The list includes medicines used for cancer, infectious diseases, cardiovascular conditions, diabetes and other major health needs.

Cancer medicines: Government statements have reported that NLEM 2022 includes 63 medicines in relevant anti-cancer categories, including some immunosuppressive and palliative-care treatments.

Connection with DPCO: Inclusion in NLEM is an important step towards scheduled-price regulation, but the list itself is not the legal price notification.

The pricing framework operates through DPCO, 2013, its Schedule I and prices notified by NPPA.

UPSC distinction: NLEM is prepared by the Ministry of Health and Family Welfare, whereas pharmaceutical price regulation is administered through the Department of Pharmaceuticals and NPPA.

Legal framework: The Drugs (Prices Control) Order, 2013 is the principal framework for pharmaceutical price regulation in India.

It was issued under the Essential Commodities Act, 1955.

The DPCO enables the government to regulate prices and monitor compliance with notified requirements.

Paragraph 4: Provides the methodology for calculating ceiling prices of scheduled formulations.

Paragraph 5: Deals with determining the retail price of specified new drugs covered by the Order.

Paragraph 13: Addresses implementation and revision of prices for scheduled formulations.

Paragraph 19: Provides extraordinary powers to fix or revise prices of drugs in the public interest under exceptional circumstances.

Paragraph 20: Restricts excessive annual MRP increases of non-scheduled formulations.

Why Paragraph 19 is important: NPPA invoked this provision in 2019 to introduce trade-margin rationalisation for selected non-scheduled cancer medicines.

The government is using the earlier intervention as the basis for its expanded approach.

Legal distinction: The Essential Commodities Act provides the enabling legal authority, while DPCO sets out the specific rules for pharmaceutical price regulation.

Regulatory enforcement: Companies must comply with applicable notified prices. Overcharging may lead to recovery proceedings and other action under the legal framework.

Market-based pricing: Scheduled drug ceilings are generally determined using market data rather than a direct calculation of each manufacturer's production cost.

Price to Retailer (PTR): PTR is the price at which the retailer obtains the medicine from its supplier.

Market share criterion: Under the relevant DPCO formula, the prices of brands and generic versions having at least 1% market share are considered.

Simple average: NPPA determines the simple average price to retailer of the qualifying products.

Retailer margin: A 16% retailer margin is then added to determine the ceiling price under the formula.

Ceiling Price = Average PTR × 1.16

Illustration: Suppose three qualifying brands of the same scheduled formulation have PTRs of ₹80, ₹100 and ₹120.

Their simple average PTR is ₹100.

After adding the 16% retailer margin, the illustrative ceiling price becomes ₹116 per relevant unit, before applicable tax treatment.

Why this matters: The method creates a common ceiling for equivalent scheduled formulations rather than separately reimbursing every manufacturer's claimed cost.

Difference from the new 30% cap: The 16% margin is a component of the market-based ceiling-price calculation for scheduled formulations.

The proposed 30% TMR is a separate control on the overall trade margin for selected non-scheduled anti-cancer medicines.

These percentages are not interchangeable.

Institutional background: The National Pharmaceutical Pricing Authority (NPPA) was established in 1997.

It functions as an attached office of the Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers.

It is an executive regulatory authority rather than a constitutional body.

Primary responsibility: NPPA implements the government's pharmaceutical pricing framework.

Its important responsibilities include:

• Fixing and revising ceiling prices of scheduled medicines.

• Fixing applicable retail prices of specified new drugs.

• Monitoring the prices of non-scheduled medicines.

• Enforcing notified pricing requirements.

• Examining overcharging and initiating recovery proceedings.

• Advising the government on pharmaceutical pricing matters.

Regulatory monitoring: NPPA uses market information and company-reported data to monitor pharmaceutical pricing.

Consumer awareness: Initiatives such as Pharma Sahi Daam help consumers access information about regulated medicine prices.

Recent decision: NPPA is expected to play the central implementation role after DGHS finalises the list of cancer medicines covered by the new intervention.

DGHS versus NPPA: DGHS provides technical and medical expertise for selecting medicines, while NPPA is responsible for decisions and notifications under the relevant pricing framework.

Importance for governance: Effective price regulation depends not only on fixing limits but also on reliable market data, manufacturer compliance, regulatory transparency and enforcement.

Previous policy experiment: In February 2019, NPPA capped trade margins at 30% of MRP for 42 selected non-scheduled anti-cancer medicines.

The intervention was undertaken under Paragraph 19 of DPCO, 2013.

It was designed to test whether limiting excessive distribution margins could reduce cancer medicine prices without fixing every manufacturer's individual selling price.

Reported outcomes: The government has reported price reductions across hundreds of brands covered by the intervention.

According to its October 2026 statement, the earlier measure produced maximum MRP reductions of up to 91% and estimated annual patient savings of ₹984 crore across 526 brands.

These figures refer to the earlier intervention and should not be confused with the projected savings from the new proposal.

Regulatory significance: The experience demonstrated that substantial reductions in the final retail price can be achieved by restricting excessive trade margins.

Limitations: The earlier measure did not permanently resolve all affordability problems.

Some patented cancer medicines remained costly even after margin restrictions were introduced.

Policy lesson: Trade-margin controls can be effective against excessive distribution mark-ups, but they may be insufficient where the underlying manufacturer price is itself very high.

The 2026 intervention therefore represents an expansion of a previously tested regulatory approach, not an entirely new method of pharmaceutical price control.

Existing regulatory gap: Non-scheduled medicines are generally subject to restrictions on annual MRP increases, but this does not necessarily prevent manufacturers from initially introducing a medicine with a very high MRP.

Difference between procurement and retail prices: A pharmaceutical product can enter the distribution chain at one price and reach the patient at a much higher price.

According to the government's October 2026 statement, analysis of non-scheduled cancer medicines found an average mark-up of approximately 170%, with some cases reaching 700% or more.

Interpreting the percentages: A mark-up expressed as a percentage of procurement price and a trade margin expressed as a percentage of MRP have different denominators.

Therefore, a 170% mark-up cannot be directly compared with a 30% MRP-based margin without converting both to a common basis.

Hospital pharmacy practices: Hospitals may purchase medicines through commercial arrangements offering discounts or incentives.

Patients receiving treatment within a hospital may have limited practical freedom to purchase medicines from competing pharmacies.

Price information: Patients often cannot determine the actual procurement price or evaluate whether the MRP represents a reasonable charge.

Regulatory objective: TMR seeks to make the distribution component of medicine pricing more reasonable and prevent the accumulation of excessive margins.

Wider issue: Experts have also raised concerns about the pricing of medical devices and consumables, including items sold through hospital pharmacies.

The government's intervention therefore raises the broader question of how to ensure fair pricing across healthcare markets, not only in cancer treatment.

Potential benefits: Medicines currently sold with unusually high trade margins may experience substantial MRP reductions after the cap becomes enforceable.

This could directly benefit patients who purchase these medicines without full insurance or public financial support.

Limitations of margin regulation: The measure does not automatically regulate the manufacturer's initial selling price.

A manufacturer with substantial pricing power may continue to sell its product to the first distributor at a high price.

Even a relatively small permitted distribution margin can therefore result in a high final MRP.

Illustration: Suppose a patented cancer medicine is supplied to the first stockist for ₹70,000.

A 30% MRP-based trade-margin ceiling would still permit an illustrative MRP of ₹1,00,000.

Although the margin is regulated, the final price could remain unaffordable for many patients.

Possibility of circumvention: Patient-rights experts have cautioned that pricing arrangements involving free stock, bundled supplies, discounts and other commercial incentives could make it difficult to determine the genuine effective procurement price.

For example, a manufacturer could invoice a quantity of medicines at a high unit price while supplying additional quantities free of charge.

If regulators examine only the formal invoice price, they may fail to capture the actual economic value of the transaction.

Patented medicines: Where a drug has limited competition, the manufacturer's selling price may remain high.

Need for monitoring: Effective implementation will require transparent supply-chain pricing and scrutiny of commercial arrangements rather than relying exclusively on declared MRPs.

Balanced assessment: Trade-margin regulation is an important affordability measure, but it is not a complete solution to the cost of modern cancer treatment.

Patented medicine: A patented medicine contains an invention protected by a valid patent.

A patent gives its holder certain exclusive rights for a limited period, subject to legal conditions and exceptions.

Patent protection can restrict unauthorised commercial manufacture and sale of the protected invention.

Patent duration: In India, the normal patent term is 20 years from the filing date of the application, subject to the applicable law.

Generic medicine: A generic medicine generally contains the same active pharmaceutical ingredient as a reference medicine, in an appropriate dosage form and strength.

It must satisfy applicable quality and regulatory requirements.

Branded generic: A branded generic is a generic medicine marketed under a commercial brand name.

Why generics are often cheaper: Multiple manufacturers can compete when the relevant patent protection has expired, is absent or does not prevent their lawful manufacture.

Competition may reduce medicine prices.

Quality requirements: Generic medicines must meet applicable standards of identity, strength, purity, quality and performance.

A lower price does not automatically mean inferior quality.

Patented versus non-scheduled: These terms refer to different aspects of a medicine.

• Patented concerns intellectual property protection.

• Scheduled concerns inclusion in the regulatory framework for notified price ceilings.

• Generic concerns the nature of the pharmaceutical product relative to a reference medicine.

• Branded concerns its commercial name.

A medicine's patent status does not, by itself, determine whether it is scheduled.

UPSC significance: The proposed intervention is important because it seeks to cover patented as well as non-patented medicines, demonstrating that patent protection and public-interest price regulation are separate legal issues.

Cancer treatment has evolved considerably beyond conventional surgery and radiation.

Chemotherapy: Chemotherapy uses medicines that destroy or inhibit rapidly dividing cells.

Because some healthy cells also divide rapidly, chemotherapy can cause side effects affecting the digestive system, blood cells, hair and other tissues.

Targeted therapy: Targeted medicines act on particular molecules or biological pathways involved in cancer-cell growth or survival.

These treatments may be suitable only for patients whose tumours possess specific molecular characteristics.

Immunotherapy: Immunotherapy seeks to strengthen or modify the immune system's ability to recognise and attack cancer cells.

Monoclonal antibodies: These are laboratory-produced proteins designed to bind to specific biological targets.

Some cancer immunotherapies use monoclonal antibodies.

Checkpoint inhibitors: Certain immunotherapies block inhibitory signals that prevent immune cells from attacking cancer cells.

Precision medicine: Precision medicine involves selecting treatment based on individual characteristics, including genetic or molecular information about the disease.

Examples: Ribociclib is a targeted medicine used in certain forms of breast cancer.

Pembrolizumab is an immunotherapy medicine used for specified cancers and clinical indications.

Why prices can be high: New therapies may involve extensive research, biological manufacturing technologies, specialised testing and patent protection.

Access challenge: These advances can improve outcomes for selected patients, but their benefits cannot be realised equitably if eligible patients cannot obtain the treatment.

Important qualification: Newer therapies are not necessarily the best option for every patient. Treatment decisions depend on the cancer type, disease stage, clinical evidence, patient condition and medical guidelines.

Disease burden: Cancer is a major non-communicable disease (NCD).

Non-communicable diseases are conditions that are not generally transmitted directly from one person to another.

Other major NCD categories include cardiovascular diseases, diabetes and chronic respiratory diseases.

India's cancer incidence: According to ICMR's National Cancer Registry Programme estimates reported by the government, India recorded an estimated 14,96,972 new cancer cases in 2023.

These are estimated incident cases, not the total number of people living with cancer.

Incidence versus prevalence: Incidence measures new cases arising during a specified period.

Prevalence measures all existing cases in a population at a particular time or over a defined period.

Increasing treatment needs: Rising population size, population ageing, changes in risk factors and improved diagnosis can all influence cancer case numbers.

Financial burden: Cancer treatment may involve consultations, diagnostic investigations, surgery, radiotherapy, repeated medication, travel and accommodation.

Out-of-pocket expenditure (OOPE): OOPE refers to healthcare expenses paid directly by households rather than covered by insurance or government programmes.

The National Health Accounts 2022–23 reported that out-of-pocket expenditure accounted for 43.4% of India's total health expenditure.

Catastrophic health expenditure: This occurs when medical costs consume such a large share of household resources that they threaten essential spending and financial stability.

Policy significance: Reducing medicine prices is one component of cancer control.

Early diagnosis, screening, specialist availability, timely treatment, palliative care and financial protection are equally important.

Equity dimension: Patients in rural, remote and low-income communities may face additional barriers, including limited specialist facilities and travel costs.

Article 21 — Protection of life and personal liberty: Article 21 guarantees the right to life and personal liberty.

The Supreme Court has interpreted the right to life broadly to include important aspects of human dignity and access to essential medical care.

Article 47 — Public health: Article 47 is a Directive Principle of State Policy.

It directs the State to regard improvement of public health, nutrition and the standard of living as among its primary duties.

Fundamental Rights versus Directive Principles: Fundamental Rights are judicially enforceable.

Directive Principles are not directly enforceable by courts but are fundamental to governance and guide lawmaking and public policy.

Public healthcare obligations: Access to essential medicines is closely connected with the ability to receive appropriate healthcare.

Excessive medicine prices may therefore have implications for the effective enjoyment of the right to health.

State responsibility: The government may use laws, public procurement, financial assistance and healthcare programmes to improve access to treatment.

Limitations: The constitutional right to health does not mean every patented medicine must automatically be supplied free of charge to every person.

The scope of particular obligations depends on statutory provisions, judicial decisions, public resources and the circumstances involved.

Relevance to pharmaceutical pricing: Price regulation provides one possible policy instrument for balancing public health, affordability and commercial rights.

This makes cancer medicine pricing an important GS2 issue concerning constitutional governance and social justice.

Purpose of patent protection: The Patents Act, 1970, governs patent rights in India.

Patent law seeks to encourage innovation by protecting qualifying inventions while also incorporating safeguards for public interest.

Section 3(d): This provision restricts patentability of certain new forms of known substances unless the statutory requirement concerning enhanced efficacy is satisfied.

It is important in preventing patents from being granted merely for qualifying minor modifications that do not meet the prescribed requirements.

Evergreening: Evergreening generally refers to strategies through which additional patent protection is sought for modifications of existing products.

Not every incremental pharmaceutical invention is prohibited; patentability depends on the statutory requirements.

Section 83: This provision sets out general principles governing the working of patented inventions, including that the benefits of patented inventions should be available to the public at reasonably affordable prices.

Section 84 — Compulsory licensing: Section 84 of the Patents Act allows an eligible applicant, subject to statutory conditions, to seek a compulsory licence after three years from the grant of a patent.

Important grounds include:

• Reasonable requirements of the public have not been satisfied.

• The invention is not available to the public at a reasonably affordable price.

• The patented invention is not worked in the territory of India.

Section 92: This provides for special compulsory-licensing arrangements in circumstances such as national emergency, extreme urgency and public non-commercial use.

Section 100 — Government use: This allows the Central Government or a person authorised by it to use a patented invention for government purposes, subject to statutory provisions.

Why the distinction matters: Compulsory licensing and government use are different legal mechanisms.

Neither should be confused with the routine process of fixing a medicine's MRP under DPCO.

Public-health significance: These provisions demonstrate that patent rights operate within a wider legal framework recognising public interest and access to medicines.

Background: A case concerning the affordability of ribociclib, a patented medicine used for certain breast cancers, brought the issue of patent protection and access to treatment before the Kerala High Court.

The matter continued as proceedings concerning the pricing of life-saving patented medicines.

Court's decision: In September 2026, the Kerala High Court considered whether Section 100 of the Patents Act could be used to improve access to expensive patented medicines.

Government powers: The Court recognised that the provision can permit government-authorised use of a patented invention, including manufacture and non-commercial supply of medicines to patients in appropriate circumstances.

Affordability assessment: The Court emphasised that the government should collect relevant information to determine whether particular patented medicines are affordable and whether existing regulatory measures provide sufficient protection.

Policy discretion: The judgment did not itself order the government to manufacture ribociclib or another particular cancer medicine.

The decision whether to invoke Section 100 in a specific case remained a matter for the Central Government, subject to the applicable legal framework.

Constitutional connection: The Court considered public-health responsibilities in light of Articles 21 and 47.

Significance: The decision highlights the legal possibility of using public-interest patent provisions where expensive medicines create serious access problems.

Balanced perspective: Pharmaceutical companies argue that patent protection and commercial returns are important for financing innovation.

Patients and public-health advocates emphasise that life-saving medicines must remain reasonably accessible.

The legal challenge is to balance these interests in accordance with Indian patent law and constitutional obligations.

Judicial scrutiny: In September 2026, the Supreme Court examined petitions concerning excessive differences between procurement prices and MRPs of medicines sold to patients.

During the proceedings, attention was drawn to a cancer medicine reportedly supplied to retailers for approximately ₹2,700 while carrying an MRP of around ₹27,000.

Main concern: The Court questioned whether existing regulations adequately protect patients from excessive pharmaceutical mark-ups.

Hospital pharmacies: The proceedings also raised concerns about patients being directed to purchase medicines through particular hospital pharmacies.

Regulatory question: The Court examined whether a stricter retailer-margin framework should extend more broadly to essential medicines and whether the distinction between scheduled and non-scheduled medicines provides sufficient consumer protection.

October developments: At the hearing on 12 October 2026, the Supreme Court questioned why the new trade-margin intervention was restricted to anti-cancer medicines.

The Union government argued that price interventions should also consider medicine availability and the wider functioning of pharmaceutical markets.

Procedural status: The matter was listed for further hearing on 27 October 2026.

These observations should not be described as a final Supreme Court judgment establishing a universal 16% margin cap for all medicines.

UPSC relevance: The case concerns judicial scrutiny of executive regulation, consumer welfare and the responsibility of the State to maintain access to essential healthcare.

India uses several policy instruments alongside pharmaceutical price regulation.

11. Ayushman Bharat — Pradhan Mantri Jan Arogya Yojana (AB PM-JAY)

AB PM-JAY provides eligible beneficiaries with health cover of ₹5 lakh per family per year for specified secondary and tertiary hospitalisation services.

Cancer treatment is included through relevant medical, surgical and radiation oncology packages.

However, coverage depends on beneficiary eligibility, approved packages, empanelled hospitals and applicable scheme rules.

It is not an unrestricted reimbursement programme for every cancer medicine.

22. Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP)

PMBJP aims to make quality generic medicines available at affordable prices through Jan Aushadhi Kendras.

The scheme operates under the Department of Pharmaceuticals and is implemented through the Pharmaceuticals and Medical Devices Bureau of India (PMBI).

Government information indicates that medicines available under the scheme are generally priced approximately 50%–80% below comparable branded medicines.

Its product basket includes medicines from several therapeutic categories, including certain cancer treatments.

However, not every advanced or patented cancer medicine is available through the scheme.

33. Affordable Medicines and Reliable Implants for Treatment (AMRIT)

AMRIT pharmacies provide selected medicines and medical products at reduced prices.

They include medicines used in treating cancer, cardiovascular diseases and other conditions.

Government reporting indicates average discounts of up to around 50% on relevant products compared with market rates.

44. Free Drugs Service Initiative

The National Health Mission supports States and Union Territories in providing essential medicines at public healthcare facilities.

This helps reduce direct expenditure by patients using public hospitals.

55. Public cancer-care infrastructure

Government initiatives also support cancer diagnosis, treatment and specialist care through public hospitals, medical colleges, regional cancer centres and related facilities.

66. Tax and customs-duty measures

Reduction or exemption of applicable duties on selected cancer medicines can lower some components of the import or supply cost.

The benefit ultimately reaching patients depends on commercial pricing and regulatory implementation.

Overall importance: A combination of price controls, generic competition, public procurement, insurance coverage and healthcare infrastructure is more effective than relying on any one mechanism.

A uniform approach may not have equal effects across all products.

7. 7.

   Hospital-level enforcement: Monitoring prices charged by hospitals and other healthcare providers may require coordination with State drug-control authorities.

8. 8.

   Patient awareness: Patients must be able to identify permitted MRPs and report suspected overcharging.

9. 9.

   Health-system limitations: Even cheaper medicines may remain inaccessible where diagnostic facilities, specialists or suitable treatment centres are unavailable.

10. 10.

    Policy coordination: Price regulation must be coordinated with intellectual property law, drug approvals, public procurement and health financing.

Production safeguards: The government's October 2026 announcement states that manufacturers will be required to maintain existing production levels as part of the intervention to protect medicine availability.

The effectiveness of this condition will depend on the detailed regulatory notification and subsequent monitoring.

Need for affordability: Essential treatment should not become inaccessible solely because patients cannot bear excessively high prices.

Need for innovation: Research into new cancer therapies requires investment and carries scientific and commercial risks.

Competitive markets: Encouraging lawful generic and biosimilar competition can help reduce prices after relevant intellectual property and regulatory requirements are satisfied.

Biosimilars: Biosimilars are biological medicines shown to be highly similar to an approved reference biological product according to applicable regulatory standards.

They are more complex to evaluate than many conventional chemically synthesised generics.

Public procurement: Government agencies can negotiate prices and purchase medicines in larger quantities to improve affordability.

Voluntary licensing: Patent holders may permit other manufacturers to produce a medicine under negotiated conditions.

Compulsory licensing: Where statutory requirements are satisfied, the government or eligible applicants may use the mechanisms available under the Patents Act.

Research support: Public funding for cancer research, domestic manufacturing capabilities and clinical research infrastructure can improve innovation capacity.

Transparency: Better information about effective transaction prices, medicine availability and public procurement costs can improve regulation.

Policy balance: A sustainable framework should reward genuine innovation while ensuring that the benefits of medical advances are accessible to patients.

Market regulation: The decision illustrates how the State may intervene when market arrangements create excessive costs for consumers of essential goods.

Public health: Affordable medicines are closely connected with the effective delivery of healthcare services.

Social justice: A serious disease can affect households across income groups, but the resulting financial burden is particularly severe for poorer families.

Consumer protection: Transparent pricing can reduce exploitation and improve patients' ability to make informed decisions.

Federal coordination: Pharmaceutical prices are regulated through a central framework, while States play significant roles in healthcare delivery and drug-control enforcement.

Judicial accountability: Recent court proceedings demonstrate how judicial scrutiny can draw attention to possible shortcomings in regulatory practice.

Industrial policy: Pharmaceutical regulation must consider India's role as a major producer of generic medicines and the importance of pharmaceutical innovation.

Economic welfare: Excessive medical expenditure can reduce household savings, disrupt consumption and increase the risk of poverty.

Long-term development: Improving medicine affordability contributes to universal health coverage and Sustainable Development Goal 3, which concerns healthy lives and well-being.

UPSC conclusion: The proposed trade-margin cap is an important regulatory intervention, but its success should be evaluated through actual reductions in patient expenditure, continued availability of medicines, fair enforcement and improved treatment access rather than the announcement of price limits alone.